metabolic dysfunction-associated steatohepatitis
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Pegozafermin (BIO89-100) (FGF21 analog) | metabolic dysfunction-associated steatohepatitis | Phase 3 | Jun 30, 2027 | — |
Upcoming milestones
metabolic dysfunction-associated steatohepatitis
Data readoutCompany profile
89bio Inc. is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.